1. Home
  2. BIDU vs INSM Comparison

BIDU vs INSM Comparison

Compare BIDU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baidu Inc. ADS

BIDU

Baidu Inc. ADS

HOLD

Current Price

$124.85

Market Cap

40.9B

Sector

Technology

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$177.67

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIDU
INSM
Founded
2000
1988
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9B
41.2B
IPO Year
2005
2000

Fundamental Metrics

Financial Performance
Metric
BIDU
INSM
Price
$124.85
$177.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
21
Target Price
$144.23
$185.84
AVG Volume (30 Days)
2.2M
3.7M
Earning Date
11-18-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.25
N/A
Revenue
$18,325,514,127.00
$447,022,000.00
Revenue This Year
N/A
$43.95
Revenue Next Year
$4.78
$130.35
P/E Ratio
$38.42
N/A
Revenue Growth
N/A
30.34
52 Week Low
$74.71
$60.40
52 Week High
$149.51
$212.75

Technical Indicators

Market Signals
Indicator
BIDU
INSM
Relative Strength Index (RSI) 54.26 40.56
Support Level $121.80 $172.65
Resistance Level $125.37 $179.33
Average True Range (ATR) 2.73 7.15
MACD 0.25 -3.04
Stochastic Oscillator 50.70 37.18

Price Performance

Historical Comparison
BIDU
INSM

About BIDU Baidu Inc. ADS

Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: